What Ozempic Face Actually Is
"Ozempic face" describes the hollowed, gaunt, or aged appearance some patients notice after rapid weight loss on Ozempic, Wegovy, or other GLP-1 medications. It's a real visual phenomenon, and the main driver appears to be the fat loss that comes with weight loss rather than a direct effect of the medication, although researchers are still studying whether the drugs play any direct role.
It's caused by losing facial fat too fast for your skin to keep up.
The same thing happens after:
- Bariatric surgery
- Significant weight loss from any cause
- Aging combined with weight loss
- Severe illness or eating disorders
The science is the same: your face has fat pads that contribute to its youthful appearance. When those fat pads shrink quickly, the skin and muscles around them haven't had time to remodel. The result is a hollowed, sometimes saggy look.
Who Gets It
Not everyone. Ozempic face is more common in:
- Older patients, because skin elasticity declines with age
- People who lose weight rapidly
- Patients with low body fat to begin with, who lose facial fat earlier
- Naturally thin-faced people, where the loss is more visible
- Those with significant sun damage or thinning skin
Younger patients with good skin elasticity may notice less change.
The 6 Ways to Prevent or Reduce It
1. Slow down the weight loss
Aim for a gradual, steady pace rather than the fastest loss you can get; your prescriber can help you set it.
This is mostly controlled by your dose schedule. Most patients on the lowest effective dose lose at a healthy pace. Pushing for the fastest possible weight loss is a recognized risk factor for more severe facial changes.
Talk to your doctor about whether a lower dose is appropriate for you if facial changes concern you.
2. Increase protein dramatically
Protein supports skin and muscle integrity during weight loss. Reduced food intake, when not carefully managed, can lead to insufficient protein intake, which is a recognized risk factor for more severe skin changes.
Ask your prescriber or a registered dietitian for a protein target that fits your goal weight and health history.
This is non-negotiable for skin quality. Skip protein, and the skin won't bounce back as well.
3. Add resistance training
Resistance training preserves muscle mass during weight loss. Weight loss on these medications includes some loss of lean mass, not just fat.
Full-body strength training helps preserve muscle during weight loss.
4. Stay hydrated and get enough fat
Skin needs water and dietary fat to look full and elastic. Severe undereating dehydrates and dulls skin.
- Stay well hydrated; ask your care team what amount fits you
- Include healthy fats in your meals
5. Consider a temporary "maintenance phase"
If your face is showing the weight loss, ask your prescriber about a maintenance phase to let your skin and muscles catch up.
This is a feature of long-term GLP-1 use, not a failure.
6. Cosmetic options if needed
For patients with significant facial volume loss, cosmetic dermatology has good options:
- Injectable fillers may help with facial volume loss when performed by a licensed clinician; like any procedure, they carry their own risks.
- Skin-tightening procedures such as radiofrequency treatments are being studied for this use, and the evidence is still limited.
Talk to a licensed dermatologist if you're considering any of these. Avoid medspas that don't have a doctor on staff.
What to Expect Long-Term
For most patients, facial changes:
- Tend to become noticeable as weight comes off
- Stabilize as weight stabilizes
If you stop GLP-1 and regain weight, the face usually fills back in, but the skin may be looser than before.
What to Skip
Several things you'll see online don't help:
- "Face yoga" has not been shown to restore lost facial volume
- Collagen powders have not been shown to restore lost facial volume
- Generic anti-aging creams don't restore lost volume
- Drastic dietary supplements for "skin health" rarely have evidence
The boring stuff (slow weight loss, protein, weights, hydration) is what works.
The Honest Take
Ozempic face is a real concern, but several of its risk factors can be managed. The patients who experience the worst version are usually those who lost weight too fast, ate too little protein, and didn't strength train.
Done right, GLP-1 weight loss can leave you looking healthier, not gaunter. The medication is a tool. How you use it determines the outcome.
For a complete guide to starting GLP-1 safely, see our complete getting-started guide.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider. Compounded medications are not FDA-approved as final products. Individual results may vary.
Frequently Asked Questions
Does Ozempic face go away when you stop taking the medication?
If you stop and regain weight, facial fat tends to return along with the weight. The skin may be slightly looser than before. If you stay at your reduced weight, the face stabilizes at the new appearance, which most patients adjust to over time.
How fast is too fast for weight loss?
Public health guidance favors gradual, steady weight loss over rapid loss. Your prescriber can help you set a pace that is gradual and steady rather than as fast as possible; faster loss is linked to more skin and muscle changes.
Can fillers fix Ozempic face?
Injectable fillers are one cosmetic option for restoring facial volume; they should be performed by a licensed clinician and, like any procedure, carry their own risks.
Does tirzepatide cause less Ozempic face than semaglutide?
There is no head-to-head comparison we can cite. Whichever medication is used, the amount and pace of weight loss are what drive facial changes. Rapid weight loss is a recognized risk factor for more severe skin changes, so ask your prescriber about a gradual pace whichever medication you use.
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.WEGOVY- semaglutide injection, solution (Prescribing Information, Revised 6/2026) · DailyMed, U.S. National Library of Medicine (FDA-approved labeling, Novo Nordisk) · accessed
- 2.Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of "Ozempic Face" (Rao S et al., Dermatol Ther (Heidelb), 2026) · PubMed Central (NIH/NLM), PMCID PMC13558510, PMID 42579223 · accessed
- 3.Effects of GLP-1 Receptor Agonists on Skin Quality: A Comprehensive Literature Review (Barone M et al., Aesthetic Plast Surg, 2026) · PubMed (NIH/NLM), PMID 42162206, DOI 10.1007/s00266-026-05820-4 · accessed
- 4.Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity (Mollero ELM et al., Nutrients, 2026) · PubMed Central (NIH/NLM), PMCID PMC13516410, PMID 42654234 · accessed
- 5.Steps for Losing Weight | Healthy Weight and Growth | CDC · Centers for Disease Control and Prevention · accessed
- 6.21 U.S. Code § 353a - Pharmacy compounding · Legal Information Institute, Cornell Law School (federal statute, FD&C Act section 503A) · accessed
- 7."Ozempic Face": An Emerging Drug-Related Aesthetic Concern and Its Treatment with Endotissutal Bipolar Radiofrequency (RF)-Our Experience (Catalfamo L et al., J Clin Med, 2025) · PubMed (NIH/NLM), PMID 40806889, PMCID PMC12346945, DOI 10.3390/jcm14155269 · accessed
Majesta Health articles are written against primary sources (FDA labeling, NIH and CDC publications, state statutes) and each one passes a documented compliance review before publication. Where an article cites external sources, they are listed at the end of that article so you can check them yourself. No article currently carries an individual physician review; when a physician reviews an article, that page will show the reviewer's name, NPI and review date.
- Written against primary sources: FDA labeling and safety communications, NIH and CDC publications, state statutes and medical board rules
- Documented compliance review against FDA, FTC and LegitScript requirements before publication
- External sources, where an article cites them, are listed at the end of that article with links to the original documents
- Compounded medications are described as not FDA-approved as final products on every page that mentions them